menu close
www.yugabyte.com
Yugabyte-Logo

YugaByte Stock

Company Profile:

Yugabyte is the company behind open source YugabyteDB, a high-performance, PostgreSQL-compatible, distributed database for cloud native applications. Built using a unique combination of high-performance document store, auto sharding, per-shard distributed consensus replication and multi-shard ACID transactions (inspired by Google Spanner), YugabyteDB serves both scale-out RDBMS and internet-scale OLTP workloads with low query latency, extreme resilience against failures and global data distribution. As a cloud native database, it can be deployed across public and private clouds as well as in Kubernetes environments with ease.

Sign up for SecondMarket™ to view the market and buy or sell YugaByte Stock
Buy + Sell

YugaByte Funding

Sign up to gain insights into YugaByte funding history, including the funding round, time period, and amount raised.

Sign Up to Unlock the Data
Date Financing Round Amount Price per share* Valuation*
Oct 13, 2021 Series C 155.26M
Price
Valuation
Oct 13, 2021 Series C 32.24M
Price
Valuation
Jan 08, 2021 Series B 47.50M
Price
Valuation
Mar 31, 2020 Series B 30.00M
Price
Valuation
Jun 12, 2018 Series A 16.98M
Price
Valuation
Nov 02, 2017 Series A 8.00M
Price
Valuation

*Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market Tape D™

Leverage Your Equity to Help Achieve More.

YugaByte Management Team

  • CCO

    Gali Kedar

  • Chief Financial Officer

    Ninos Sarkis

  • CFO

    Anthony Russo

  • CFO

    Malvin Hoxhallari

  • Co-Founder, President, Director

    Josh Goldman

  • Director

    Frederick Ball

  • Chairman

    John R. Stuelpnagel

YugaByte Major Investors

  • Sapphire Ventures LLC

  • Wipro Ventures

  • Meritech Capital Partners

  • Wells Fargo Strategic Capital

  • Alkeon Capital

  • Lightspeed Venture Partners

  • Greenspring Associates, Inc

  • Greenspring Associates, Inc

  • 8VC

  • Dell Technologies Capital

Learn More About YugaByte Stock

Buy YugaByte Stock
01
YugaByte stock does not trade on public stock exchanges. YugaByte stock is considered a private security and you need to be an accredited investor to purchase shares. To invest in YugaByte stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market. Get started to begin exploring private market opportunities.
Sell YugaByte Stock
02
YugaByte Stock does not trade on public stock exchanges. In order to sell YugaByte shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors. Get started to begin exploring private market opportunities.
YugaByte Stock Price
03
YugaByte does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the Tape D™ database from Nasdaq Private Market, you can view YugaByte share price and other valuable private market data. Get started to begin exploring the Nasdaq Private Market Tape D™ database.
YugaByte Stock Ticker Symbol
04
There is no ticker symbol for YugaByte stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company “street” name or legal name. Get started to begin exploring the Nasdaq Private Market Tape D™ database.
Criteria to Sell YugaByte Stock
05
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell YugaByte stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Criteria to Buy or Invest in YugaByte Stock
06
Currently, Nasdaq Private Market only works with institutional investors to purchase private company stock. In order to invest in YugaByte stock you need to be an institutional investor. Get started to begin exploring the Nasdaq Private Market Tape D™ database.
YugaByte Stock Settlement
07
Once you buy or sell stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
YugaByte IPO
08
YugaByte is a private company and has not had an IPO. There is currently no YugaByte IPO price. Get started to begin exploring the Nasdaq Private Market Tape D™ database and gain access to actionable data related to YugaByte IPO.

*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.

Sign up for SecondMarket™ to view the market and buy or sell YugaByte Stock
Buy + Sell

*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.

Other Companies

Strava Inc-Logo

Strava

Mobile and online-based solutions for athletes.

Harnessinc-Logo

Harness

Continuous Delivery-as-a-Service platform designed to provide a simple, safe and secure way for engineering and DevOps teams to release applications into production.

Iris Telehealth-Logo

Iris Telehealth

Telepsychiatry services for community mental health systems.

Seatgeek-Logo

SeatGeek

Ticket search engine that aggregates ticket listings for live sports, concerts, and theater events.

Trmlabs-Logo

TRM Labs

Developed a token relationship management that includes solutions for on-chain customer due diligence, transaction monitoring, and relationship management.

Nutcracker Therapeutics-Logo

Nutcracker Therapeutics

Uses high-technology engineering and advanced biosynthesis to advance mRNA therapeutics through strategic partnerships with clinical institutions and pharmaceutical/biotech companies.

Source: Nasdaq Private Market Tape D™